Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Heron Therapeutics, Inc.NASDAQ: HRTX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $2.53M (cash outflow) fell 61.3% year over year, behind the +679.8% change in trailing-twelve-month net change in cash. Sequentially, it fell 82.5% from the prior quarter.

Context

  • Net change in cash amounted to 1.8% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -61.3% toward the trailing-twelve-month pace of +679.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.53M-82.5% QoQ
Last fiscal yearDec 2025
$2.85M+199.0% YoY
LTMMar 2026
$6.85M+679.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-61.3%——
1 year+199.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
2.85M USD
Year-over-year change
+199.0%

Net Change in Cash vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's LTM Mar 2026 net change in cash of $6.85M is the 9th largest of the 10 companies compared; the peer median is $18.15M.
  • Its year-over-year change of +679.8% is the 2nd highest of 9, against a peer median of +305.2%.
  • Net change in cash amounts to 4.5% of revenue for HRTX, versus a peer median of 70.0%.
HRTX Competitors Peer median
Net Change in Cash for HRTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$136.08M +196.3%—243.6%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$90.39M +288.1%——
TARAProtara Therapeutics, Inc.LTM Mar 2026$76.72M -295.6%+113.7%—
CHRSCoherus Oncology, Inc.LTM Mar 2026$32.8M +118.5%-52.8%70.0%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$22.25M +387.0%-41.5%29.1%
OABIOmniAb, Inc.LTM Mar 2026$18.15M +322.3%—62.8%
MDWDMediWound Ltd.LTM Mar 2026$13.99M +520.6%—96.6%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$11.75M +1066.8%+102.1%—
HRTXHeron Therapeutics, Inc.LTM Mar 2026$6.85M +679.8%—4.5%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$4.8M ———
Peer median (excluding HRTX) $18.15M+305.2%+30.3%70.0%

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
Deferred Income Tax1.63M0000
Stock-Based Compensation46.85M42.98M32.85M12.96M10.34M
Change in Working Capital(35.08M)(10.51M)16.79M(27.6M)(31.88M)
Accounts Receivables6.35M(16.55M)(8.09M)(18.74M)(10.71M)
Inventory(6.48M)(6.19M)12.46M(11.05M)(31.05M)
Accounts Payables3.28M(578K)15K8.47M(2.72M)
Other Working Capital(38.23M)12.81M12.4M(6.28M)12.59M
Other Non-Cash Items904K(251K)(773K)3.2M11.83M
Operating Cash Flow(203.35M)(146.91M)(58.79M)(22.53M)(27.59M)
Capital Expenditures(3.02M)(1.83M)(1.55M)(1.71M)(317K)
Acquisitions (Net)32K227K13K27K0
Purchases of Investments(129.22M)(145.68M)(87.66M)(103.09M)(50.79M)
Sales of Investments164.94M143.96M107.19M123.48M67.01M
Other Investing Activities000098K
Investing Cash Flow32.73M(3.32M)18M18.71M16.01M
Debt Repayment148.96M024.35M0145.11M
Common Stock Issued7.07M75.06M29.76M940K19.32M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(150M)
Financing Cash Flow156.03M75.06M54.11M940K14.43M
Effect of Forex Changes00000
Net Change in Cash(14.6M)(75.18M)13.31M(2.88M)2.85M
Free Cash Flow(206.38M)(148.74M)(60.33M)(24.24M)(27.91M)

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.